The Breast Cancer Research Foundation Announces $19.1 Million Gift for the Evelyn H. Lauder Founder’s Fund
Funds Will Support Research That Will Have Implications Beyond Breast Cancer
New York, January 10, 2013 - The Breast Cancer Research Foundation® today announced an additional infusion of funds resulting from the “Magnificent Jewels” auction at Sotheby’s that took place on December 5, 2012. The sale raised $19.1 million from more than 35 pieces of jewelry from the Evelyn H. Lauder and Estée Lauder collections. All proceeds will benefit the Evelyn H. Lauder Founder’s Fund, created in memory of the late Chairman who died on November 12, 2011. The Founder’s Fund now totals $27 million.
“On behalf of the Lauder family, we are pleased that the beautiful and unique pieces owned by my dear wife Evelyn and my mother Estée have found new homes, while at the same time raising significant funds for The Breast Cancer Research Foundation,” said Leonard A. Lauder, Acting Chairman, BCRF and Palm Beach resident. “Our hope is that one day this disease will be a thing of the past. The proceeds from the sale will support the critical research necessary to bring us closer to achieving our goal.”
These funds will make it possible for BCRF to design and conduct a comprehensive, international project to analyze the molecular abnormalities in metastatic breast cancer. This follows last month’s announcement of plans for the first phase of the Evelyn H. Lauder Founder’s Fund project, which will include an extensive, international, collaborative analysis of the molecular abnormalities in metastatic breast cancer in the context of defined treatments and outcomes, which has never before been conducted. Evelyn Lauder’s mission was to bring about prevention and a cure for the disease; this fund in her memory provides the means to fulfill her goal.
"The Founder’s Fund will enable us to find out the changes in DNA, RNA, and proteins that make metastatic breast cancer--and probably many other types of cancer--so destructive and life-threatening,” said BCRF Scientific Director Larry Norton, MD, Memorial Sloan-Kettering Cancer Center. “Moreover,
we will be able to examine why some cancers respond extremely well to therapy while others do not
and potentially change those resistant tumors into sensitive ones. The extraordinary collection of dedicated scientists and clinicians in our organization, our international scope, and our laser-like focus on quality research for the purpose of eradicating breast cancer are now energized. This is a most exciting moment in history.”